Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-17

Clinical Trial Update: Rimegepant in Moderate Plaque-type Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 study of rimegepant for moderate plaque-type psoriasis has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rimegepant (rimegepant)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2025-07-17